Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

